References
- Odom L F, August C S, Githens J H, Humbert J R, Morse H, Peakman D, et al. Remission of relapsed leukaemia during a graft-vs.-host reaction. A ‘graft-vs.-leukaemia reaction’ in man?. Lancet 1978; 2: 537–540
- Weiden P L, Sullivan K M, Fluornoy N, Storb R, Thomas E D. Antileukemic effect of chronic graft vs. host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533
- Ruiz-Argüelles G J, Gómez-Almaguer D. Braking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693–1699
- Ruiz-Argüelles G J, López-Martínez B, Santellán-Olea M R, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, et al. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution. Leukemia Lymph 2002; 43: 1509–1511
- Furukawa T, Hashimoto S, Inano K, Yamazaki F, Takeda H, Kakihara T, et al. Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Rinsho Ketsueki 2001; 42: 488–495
- van Leeuwen J E, van Tol M J, Joosten A M, Wijnen J T, Verweij P J, Khan P M, et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83: 3059–3067
- Gómez-Almaguer D, Ruiz-Argüelles G J, Tarín-Arzaga L C, González-Llano O, Jaime-Pérez J C, López-Martínez B, et al. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transpl 2003; 9: 157–161
- Ruiz-Argüelles G J, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre C H, Vela-Ojeda J, García-Ruiz-Esparza M A. for the Latin American Cooperative Oncohematology Group: the early referral for reduced-intensity stem cell transplantation in patients with Ph1(+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043–1047
- Ruiz-Argüelles G J. The Mexican approach to conduct allogeneic stem cell transplantation: braking dogmata and facing the Matthew effect. Hematology 2005; 10(Suppl 1)154–160
- Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman P S, Ku S, Gutterman J U, et al. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia 1992; 6: 754–760
- Sloand E, Childs R W, Solomon S, Greene A, Young N S, Barrett A J. The graft-vs.-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897–901